AstraZeneca’s Farxiga gets US FDA approval to reduce risk of CV death
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER phase III trial. Farxiga was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF).
